Physician profile
Paige Marietta Griffith
NPI 1639636731
$105,914.90
in general payments reported to CMS, 2019-2025
27 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $727 · 2022: $4,634 · 2023: $26K · 2024: $44K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $17K · Consulting Fee: $17K · Food and Beverage: $6,671 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,450.00 |
| Travel and Lodging | $17,395.10 |
| Consulting Fee | $16,938.33 |
| Food and Beverage | $6,671.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $75,630.15 | 2021-2025 | Imfinzi, Tagrisso |
| Astellas Pharma US INC | $19,021.09 | 2023-2024 | Vyloy |
| Jazz Pharmaceuticals INC. | $2,100.73 | 2022-2025 | |
| Helsinn Healthcare Sa | $1,770.07 | 2022 | |
| Eisai INC. | $1,685.00 | 2021-2023 | |
| Exelixis INC. | $1,552.38 | 2022-2025 | Cabometyx |
| Daiichi Sankyo INC. | $877.64 | 2021-2025 | Datroway, Enhertu |
| Incyte Corporation | $660.63 | 2022-2025 | Zynyz, Pemazyre |
| Amgen INC. | $322.47 | 2022-2023 | Lumakras, Kyprolis |
| Secura Bio, INC. | $210.58 | 2023 | Copiktra |
| Janssen Biotech, INC. | $201.78 | 2022-2025 | Rybrevant, Carvykti, Tecvayli |
| Gilead Sciences, INC. | $186.17 | 2023 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $181.67 | 2025 | |
| Genmab U.S., INC. | $154.57 | 2025 | Epkinly |
| Syndax Pharmaceuticals, INC. | $143.87 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fennec Pharmaceuticals, INC. | $135.72 | 2025 | Fyarro |
| Seagen INC. | $124.97 | 2023 | Tivdak |
| Adc Therapeutics America, INC. | $124.50 | 2022 | |
| Glaxosmithkline, LLC. | $121.11 | 2022 | |
| Karyopharm Therapeutics INC. | $119.32 | 2023 | Xpovio |
| Genentech USA, INC. | $114.00 | 2022 | |
| Kite Pharma, INC. | $105.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.58 | 2022 | |
| Merck Sharp & Dohme LLC | $103.49 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $94.21 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $49.55 | 2023 | |
| Janssen Scientific Affairs, LLC | $19.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.